lomustine has been researched along with Abnormalities, Autosome in 10 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| " First- and second-line therapeutics for glioblastomas are alkylating agents, including the chloroethylating nitrosoureas (CNU) lomustine, nimustine, fotemustine, and carmustine." | 3.83 | Targeting Homologous Recombination by Pharmacological Inhibitors Enhances the Killing Response of Glioblastoma Cells Treated with Alkylating Drugs. ( Berte, N; Borgmann, K; Kaina, B; Nikolova, T; Piecha, N; Piée-Staffa, A; Wang, M, 2016) |
| "Neither the number of chromosomal aberrations nor the number of SCE were affected by the addition of 1000 micrograms/ml taurine to the culture medium." | 1.28 | Genotoxicity of tauromustine, a new water soluble taurine-based nitrosourea. I. Mutagenic and clastogenic activity of tauromustine in vitro. ( Hartley-Asp, B, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (40.00) | 18.7374 |
| 1990's | 2 (20.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 2 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Berte, N | 1 |
| Piée-Staffa, A | 1 |
| Piecha, N | 1 |
| Wang, M | 1 |
| Borgmann, K | 1 |
| Kaina, B | 1 |
| Nikolova, T | 1 |
| Idbaih, A | 1 |
| Dalmasso, C | 1 |
| Kouwenhoven, M | 1 |
| Jeuken, J | 1 |
| Carpentier, C | 1 |
| Gorlia, T | 1 |
| Kros, JM | 2 |
| French, P | 1 |
| Teepen, J | 1 |
| Broët, P | 1 |
| Delattre, O | 1 |
| Mokhtari, K | 1 |
| Sanson, M | 1 |
| Delattre, JY | 1 |
| van den Bent, M | 1 |
| Hoang-Xuan, K | 1 |
| Buckner, JC | 1 |
| Gesme, D | 1 |
| O'Fallon, JR | 1 |
| Hammack, JE | 1 |
| Stafford, S | 1 |
| Brown, PD | 1 |
| Hawkins, R | 1 |
| Scheithauer, BW | 1 |
| Erickson, BJ | 1 |
| Levitt, R | 1 |
| Shaw, EG | 1 |
| Jenkins, R | 1 |
| van den Bent, MJ | 1 |
| Looijenga, LH | 1 |
| Langenberg, K | 1 |
| Dinjens, W | 1 |
| Graveland, W | 1 |
| Uytdewilligen, L | 1 |
| Sillevis Smitt, PA | 1 |
| Jenkins, RB | 1 |
| Gebhart, E | 1 |
| Lösing, J | 1 |
| Wopfner, F | 1 |
| Lambert, B | 1 |
| Ringborg, U | 1 |
| Lindblad, A | 1 |
| Hartley-Asp, B | 1 |
| Koldamova, RP | 1 |
| Lefterov, IM | 1 |
| Pedersen-Bjergaard, J | 1 |
| Osterlind, K | 1 |
| Hansen, M | 1 |
| Philip, P | 1 |
| Pedersen, AG | 1 |
| Hansen, HH | 1 |
| Vyas, RC | 1 |
| Adhvaryu, SG | 1 |
| Shah, VC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| PHASE III STUDY OF ADJUVANT PROCARBAZINE, CCNU AND VINCRISTINE CHEMOTHERAPY IN PATIENTS WITH HIGHLY ANAPLASTIC OLIGODENDROGLIOMA[NCT00002840] | Phase 3 | 350 participants (Anticipated) | Interventional | 1996-08-31 | Completed | ||
| PHASE II STUDY OF PREIRRADIATION PCV CHEMOTHERAPY IN PATIENTS WITH SUPRATENTORIAL LOW-GRADE GLIOMAS[NCT00002806] | Phase 2 | 43 participants (Actual) | Interventional | 1996-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for lomustine and Abnormalities, Autosome
| Article | Year |
|---|---|
Genomic aberrations associated with outcome in anaplastic oligodendroglial tumors treated within the EORTC phase III trial 26951.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Chr | 2011 |
Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Chromosome Aber | 2003 |
8 other studies available for lomustine and Abnormalities, Autosome
| Article | Year |
|---|---|
Targeting Homologous Recombination by Pharmacological Inhibitors Enhances the Killing Response of Glioblastoma Cells Treated with Alkylating Drugs.
Topics: Animals; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Cell Survival; Chromosome A | 2016 |
Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features.
Topics: Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Chromosome Aberrations; Chromosomes | 2003 |
Chromosome studies on lymphocytes of patients under cytostatic therapy. I. Conventional chromosome studies in cytostatic interval therapy.
Topics: Adult; Aged; Antineoplastic Agents; Chromosome Aberrations; Chromosomes; Drug Administration Schedul | 1980 |
Prolonged increase of sister-chromatid exchanges in lymphocytes of melanoma patients after CCNU treatment.
Topics: Chromosome Aberrations; Chromosomes, Human; Crossing Over, Genetic; Humans; Lomustine; Lymphocytes; | 1979 |
Genotoxicity of tauromustine, a new water soluble taurine-based nitrosourea. I. Mutagenic and clastogenic activity of tauromustine in vitro.
Topics: Antineoplastic Agents; Cell Cycle; Chromosome Aberrations; Humans; In Vitro Techniques; Lomustine; L | 1992 |
Synergistic effect of CCNU and bleomycin on human lymphocytes exposed at late G1 and G2 states of the cell cycle.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cell Cycle; Chromosome Aberrations; Drug | 1991 |
Acute nonlymphocytic leukemia, preleukemia, and solid tumors following intensive chemotherapy of small cell carcinoma of the lung.
Topics: Acute Disease; Carcinoma, Small Cell; Chromosome Aberrations; Chromosome Disorders; Cyclophosphamide | 1985 |
Effects of CCNU therapy on human chromosomes.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Chromosome Aberrations; Female; Humans; Lomust | 1988 |